A Randomized Controlled Trial to Evaluate the Cariostatic Efficacy of Nano Silver Fluoride (NSF) vs. Silver Diamine Fluoride (SDF) in Children
Sponsor study identifier
interventional
72
1 country
1
Study Start
October 1, 2026
Actual (reported)Primary Completion
October 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study, titled "A Randomized Controlled Trial to Evaluate the Cariostatic Efficacy of Nano Silver Fluoride (NSF) vs. Silver Diamine Fluoride (SDF) in Children" (Study Number: ATSU-YI-NSF 2025), is sponsored by Young Innovations and conducted at the Arizona School of Dentistry \& Oral Health (ASDOH) at A.T. Still University in Mesa, Arizona, under Principal Investigator Marc Shlossman, DDS, MS. The primary objective is to validate and compare the cariostatic efficacy of Nano Silver Fluoride (ClearDefense®) against Silver Diamine Fluoride (AdvantageArrest®) in pediatric dental patients with active carious lesions on primary molars and first permanent molars. Designed as a non-inferiority trial, it evaluates whether Nano Silver Fluoride provides comparable caries-arresting effects while assessing patient, parent, and provider acceptance, tooth color changes, and overall product safety. The trial is structured as a six-month, double-blind, parallel-group, single-site randomized controlled study with an optional twelve-month follow-up visit. To achieve a target sample size of 60 evaluable subjects (30 per treatment group) while accounting for a projected 20% dropout rate, a total of 72 pediatric participants will be recruited. Subjects are randomly assigned to treatment arms using an online random number generator. Allocation concealment and double-blinding are maintained by a third-party study coordinator who prepares treatment supplies on preset trays, keeping trial investigators, outcome examiners, and participants masked to product identity. Eligible participants include medically healthy children aged 6 to 10 years who present with at least one primary molar or permanent first molar containing active occlusal or proximal caries classified as ICDAS II Stage 3 through 6. Children and their parents or guardians must read and understand English or Spanish, provide written assent and consent, and agree to attend all required study visits. Exclusion criteria apply to children with known allergies to fluoride or silver, significant systemic conditions, ulcerative oral lesions, or conditions reducing salivary flow, as well as target teeth with loose roots, pulpal involvement, or existing restorations. At the baseline visit, active carious lesions receive a single topical application of either ClearDefense® (3% sodium fluoride + 0.2% silver ion) or AdvantageArrest® (38% silver diamine fluoride) for at least one minute. Mandatory study appointments occur at baseline, 3 months, 6 months, and an optional 12 months, incorporating clinical oral examinations, tooth cleaning, radiographs, intraoral photographs, and digital tooth shade assessments using a Vita Easyshade V spectrophotometer. The primary response variable is the clinical status of the carious lesion (active vs. arrested) measured at 3 and 6 months. Secondary outcome measures include pre- and post-treatment tooth color changes, parent-reported quality of life via the Early Childhood Oral Health Impact Scale (ECOHIS), child satisfaction regarding taste (using the TASTY scale at baseline) and tooth appearance, parent treatment acceptability, investigator ease-of-use feedback at study closeout, and documentation of adverse events including soft tissue staining or localized pain.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 29, 2026
Actual (reported)October 1, 2026
Actual (reported)October 6, 2026
Actual (reported)October 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Change in the Carious Lesion Status after Treatment
Carious teeth will be determined using ICDAS II criteria, Stage 3-4 (moderate stage caries) or Stage 5-6 (advanced stage caries) on the occlusal and/or proximal surface(s). The carious lesion is deemed "active" if there is a greater likelihood of progression into the deeper layers of tooth structure. After treatment with the randomly assigned study intervention, using a ball-tip probe, a carious lesion will be scored as active, if the lesion feels soft or leathery on gently probing the dentin. The carious lesion will be scored as arrested if the lesion feels hard on gently probing the dentin. The initial examiner who applies the intervention will be blinded to the study product and will record their score(s) for each treated lesion. A second examiner will be blinded to the study product and to the score(s) recorded by the initial examiner; they will record their score(s) separately.
Change in carious lesion status post-treatment from Baseline to 3 months, and 3 months to 6 months. There is an optional assessment for volunteers to return to assess change in carious lesion status from 6 months to 12 months.
Change in Tooth Color/Shade from Baseline to Post-Treatment
Tooth color/shade will be measured at Baseline pre- and post-teatment; then comparing post-treatment to color/shade at 3 months and at 6 months. There is an option for volunteers to return to assess tooth color/shade from post-treatment at 12 months
Early Childhood Oral Health Impact Scale (ECOHIS)
Changes in ECOHIS will be compared from Baseline to 6 months, with an optional 12 month visit when ECOHIS scores will be compared to both Baseline and 6 months.
Status of Child Behavior During Treatment
The status of the child's behavior is recorded post-treatment at the initial (Baseline) visit only.
Status of Child Satisfaction with Appearance of Treated Teeth (Patient Reported Outcome Measure)
Child satisfaction with the appearance of their teeth will be recorded immediately post-treatment at Baseline, then compared to Baseline at 3 months and 6 months. There will be an optional 12 month score to compare against the Baseline score.
Status of Child Satisfaction with Product Taste (Patient Reported Outcome Measure)
The child's TASTY score will be recorded immediately post-treatment at the initial (Baseline) visit only.
Participants receive a single topical application of ClearDefense® (3% sodium fluoride + 0.2% silver ion) to active carious lesions
Participants receive a single topical application of AdvantageArrest® (38% silver diamine fluoride) to active carious lesions
The intervention consists of a single topical application of either ClearDefense® Nano Silver Fluoride (3% sodium fluoride + 0.2% silver ion) or AdvantageArrest® Silver Diamine Fluoride (38% SDF) directly onto active carious lesions on primary molars or first permanent molars. Prior to treatment, visible plaque is removed using a tapered brush prophy angle, baseline tooth shade is recorded, and the target teeth are isolated with cotton rolls and gauze before being dried with an air-water syringe. To maintain blinding, a study coordinator dispenses two drops of the assigned agent into a dappen dish, and the study investigator applies the product across the entire carious lesion using a microbrush, allowing it to sit for at least one minute while soft tissues are retracted to avoid staining. Finally, excess product is wiped away with gauze or a cotton roll, and participants are instructed to refrain from eating or drinking for at least 30 minutes post-application.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Arizona School of Dentistry & Oral Health (ASDOH), A.T. Still University
Mesa, Arizona, 85206, United States
Mortazavi SMJ. Re: Are electromagnetic fields in incubators a risk factor for autism? Acta Paediatr. 2017 Dec;106(12):2063. doi: 10.1111/apa.14055. Epub 2017 Sep 24. No abstract available.
Viana PHL, Schvarcz CA, Danics LO, Besztercei B, Aloss K, Bokhari SMZ, Giunashvili N, Bocsi D, Koos Z, Benyo Z, Hamar P. Heat shock factor 1 inhibition enhances the effects of modulated electro hyperthermia in a triple negative breast cancer mouse model. Sci Rep. 2024 Apr 8;14(1):8241. doi: 10.1038/s41598-024-57659-x.
Marc Shlossman Associate Director of Clinical Research, DDS, MS
CONTACT
First Submitted
September 29, 2026
First Posted
October 6, 2026
Study Start
October 1, 2026
Actual (reported)Primary Completion
October 31, 2027
EstimatedContact the study team to confirm eligibility.
Cheng Y, Wang T, Lv X, Li R, Yuan L, Shen J, Li Y, Yan T, Liu B, Wang L. Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer. Cancer Manag Res. 2020 Mar 19;12:2069-2078. doi: 10.2147/CMAR.S245425. eCollection 2020.
Pahel BT, Rozier RG, Slade GD. Parental perceptions of children's oral health: the Early Childhood Oral Health Impact Scale (ECOHIS). Health Qual Life Outcomes. 2007 Jan 30;5:6. doi: 10.1186/1477-7525-5-6.
Michaeli L, Davis DM, Foxton R. Denture loss: an 8-month study in a community dental setting. Gerodontology. 2007 Jun;24(2):117-20. doi: 10.1111/j.1741-2358.2007.00133.x.
Nezam S, Mukherjee CG, Shukla JN, Jha A, Khan SA, Tanwar AS. Comparative Evaluation of Efficacy of Obturation Techniques in Deciduous Teeth Using Cone-beam Computed Tomography: An In Vivo Study. Int J Clin Pediatr Dent. 2021 Jan-Feb;14(1):75-80. doi: 10.5005/jp-journals-10005-1897.
Huang X, Yang X, Huang J, Wei L, Mao Y, Li C, Zhang Y, Chen Q, Wu S, Xie L, Sun C, Zhang W, Wang J. Correction: Human amnion mesenchymal stem cells promote endometrial repair via paracrine, preferentially than transdifferentiation. Cell Commun Signal. 2024 Jun 13;22(1):326. doi: 10.1186/s12964-024-01706-7. No abstract available.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 19, 2026
Record last verified: 2026-10
Individual participant data (IPD) will not be made available to outside researchers, as the protocol limits data access strictly to authorized study personnel and the study sponsor. All clinical findings will be de-identified, maintained on secure university servers, and reported exclusively in aggregate form to safeguard participant confidentiality. Furthermore, in accordance with institutional data management procedures, all electronic study records will be permanently deleted three years following trial completion.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: